ArticleRMD open2026
Rare variants in genes related to inborn errors of immunity in patients with rheumatoid arthritis and secondary immunodeficiency.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTreatment of rheumatoid arthritis (RA) relies on immunomodulatory drugs that can compromise immunity, inducing secondary immunodeficiency (SID). However, features of SID, such as hypogammaglobulinaemia and severe/recurrent infections, occur in only a minority of patients, suggesting a potential underlying genetic predisposition. Given the expanding spectrum of genes implicated in inborn errors of immunity (IEIs) and the fact that IEIs can present with rheumatic manifestations, we hypothesised that a subset of patients with RA with SID harbour IEI-related variants.
methodsWe screened 701 patients with RA for SID, defined as persistent hypogammaglobulinaemia or susceptibility to infections requiring prophylactic anti-infective therapy. Patients with SID underwent targeted whole-exome sequencing to identify rare variants in IEI-associated genes.
resultsAmong 701 evaluated patients, 70 (10%) had SID. SID was more frequently observed in patients with earlier onset of RA, seronegative disease and in those receiving rituximab therapy. Genetic analysis identified 17 putatively pathogenic variants in 15 of 70 patients with SID (21.4%). All variants were monoallelic, with 7 of 17 (41.2%) affecting genes involved in canonical NF-κB signalling. Two patients (3.1%) harboured variants previously reported as pathogenic.
conclusionsAlthough rare, underlying IEIs can account for immunodeficiency in patients with RA. Identifying patients with IEIs among those with RA may have important implications for disease management, as it can guide the selection of immunomodulatory therapy and help prevent infectious complications. Furthermore, it may refine our interpretation of drug safety, particularly in cases of unusual infections that may instead be attributable, rather, to an underlying germline defect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.